stockrowResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025.
- Revenue
- +5.93%
- EPS
- +23.1%
- Free cash flow
- −9.79%
- Total debt
- −38.9%
Quarter to September 2026, against a year earlier
Follow RMD
Alert me
ResMed Inc. (RMD) EPS (diluted)
ResMed Inc.'s EPS (diluted) for fiscal 2026 was $10.43, up 9.67% from $9.51 in fiscal 2025. Over the twelve months to 30 September 2026 it was $10.98. Over the past ten years it has ranged from $2.19 (fiscal 2018) to $10.43 (fiscal 2026) — the current reading is the highest in ten years. EPS (diluted) has risen for 5 consecutive fiscal years. ResMed Inc. ranks 1st of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | $10.43 | 9.67% |
| FY2025 | $9.51 | 37.43% |
| FY2024 | $6.92 | 13.63% |
| FY2023 | $6.09 | 14.91% |
| FY2022 | $5.30 | 63.58% |
| FY2021 | $3.24 | (24.12%) |
| FY2020 | $4.27 | 52.50% |
| FY2019 | $2.80 | 27.85% |
| FY2018 | $2.19 | (8.75%) |
| FY2017 | $2.40 | (3.61%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $2.92 | 10.61% |
| Jun 2026 | $2.64 | (3.65%) |
| Mar 2026 | $2.74 | 2.24% |
| Dec 2025 | $2.68 | 13.08% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| RMD ResMed Inc. | $10.98 |
| WST West Pharmaceutical Services, Inc. compare | $8.91 |
| ALGN Align Technology, Inc. compare | $6.87 |
| BDX Becton, Dickinson and Company compare | $3.32 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| ALC Alcon compare | $1.31 |
| SOLV Solventum Corporation compare | $0.89 |
| MDLN Medline Inc. compare | $0.68 |
| BAX Baxter International Inc. compare | −$1.41 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement